www.GastroToday.com
LightNews LightNews
banner
gastrotoday.bsky.social
www.GastroToday.com
@gastrotoday.bsky.social
5 followers 17 following 8 posts
GastroToday.com features breaking news, commentary, and updates to inform healthcare professionals on the latest research and best clinical practices in gastroenterology | www.GastroToday.com
Posts Replies Media Videos
gastrotoday.bsky.social
Ten-year #EpiIBD data show that earlier, more frequent use of biologics and small molecules did not improve long-term outcomes in #CrohnsDisease, with similar rates of surgery and progression across Europe. #GISky #IBDSky

Read further:
Earlier, More Intensive Advanced Therapy Fails to Improve Long-Term Crohn's Disease | Docwire News
Earlier and more frequent use of advanced therapies, including biologics and small molecules, did not translate into improved long-term outcomes for Crohn's disease across Europe.
www.docwirenews.com
December 30, 2025 at 1:27 AM
gastrotoday.bsky.social
A meta-analysis suggests #MycophenolateMofetil may be a steroid-sparing option for adults with treatment-resistant #IBD, with ~60% achieving remission early and sustained benefit at 6 months in many patients.
#GISky #IBDSky

Read more at the link:
Mycophenolate Mofetil Achieves Meaningful Remission in Treatment-Resistant IBD | Docwire News
Mycophenolate mofetil may offer a viable treatment option for patients with inflammatory bowel disease who do not respond to conventional therapies.
www.docwirenews.com
December 23, 2025 at 1:27 AM
gastrotoday.bsky.social
Etrasimod significantly improved both induction & maintenance remission in adults with #UlcerativeColitis. These findings add to growing evidence for S1P receptor modulation and highlight regional differences in UC treatment. #GISky #IBDSky

Read more at the link!
Etrasimod Improves Induction and Maintenance Remission for UC | Docwire News
Oral etrasimod significantly improved both induction and maintenance remission rates in adults with moderately to severely active ulcerative colitis.
www.docwirenews.com
December 20, 2025 at 2:32 AM
gastrotoday.bsky.social
Brain-gut behavior therapies like IBS-focused CBT and gut-directed hypnotherapy significantly improved global symptoms in adults with #IrritableBowelSyndrome. These behavioral approaches continue to stand out as effective, evidence-based tools in IBS care.

Read more at the link!
#GISky #IBSSky
Brain-Gut Behavioral Therapies for IBS | Docwire News
Behavioral therapies, especially those classed as brain-gut behavior therapy, significantly improve global symptoms in adults with irritable bowel syndrome.
www.docwirenews.com
December 18, 2025 at 1:28 AM
gastrotoday.bsky.social
Did you miss Dr. Lok's explanation on why universal newborn #vaccination against #HepatitisB remains essential for #HBV prevention? Catch the video at the link below!

www.docwirenews.com/post/importa...

#GISky #LiverSky
Scheduling Hep B Vaccination for Infants | Docwire News
Anna Lok, MD, discusses the importance of the universal birth-dose strategy for the hepatitis B vaccine.
www.docwirenews.com
December 15, 2025 at 10:27 PM
gastrotoday.bsky.social
Data from the SHINE-1 trial highlight encouraging efficacy of #mirikizumab in children with #UlcerativeColitis and support its use as a potential emerging option for younger patients. #GISky #IBDSky
Mirikizumab for Pediatric UC | Docwire News
The phase 2 SHINE-1 trial found mirikizumab was safe and effective among pediatric patients with ulcerative colitis.
www.docwirenews.com
December 12, 2025 at 11:32 PM
gastrotoday.bsky.social
A study of 221k #Veterans with cirrhosis found that mental health diseases, especially alcohol/substance use disorders, significantly increase #HCC risk. Findings emphasize multidisciplinary care for high-risk patients.
#GISky #LiverSky

Read more at the link:

www.docwirenews.com/post/associa...
Mental Health and HCC Among Veterans | Docwire News
A retrospective study found mental health diseases significantly increased the risk of HCC and were associated with active HCV among veterans with cirrhosis.
www.docwirenews.com
December 11, 2025 at 1:28 AM
gastrotoday.bsky.social
Watch Dr. Anna Lok on #HepatitisB: Infants face a 90% risk of chronic #HBV if infected early. The birth-dose vaccine is safe and effective. Dr. Lok, of University of Michigan Medicine, explains why universal newborn #vaccination remains essential. #GISky #LiverSky
www.docwirenews.com/post/importa...
December 8, 2025 at 10:28 PM